

Nicholas Lintzeris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/109997/publications.pdf>

Version: 2024-02-01

156
papers

4,968
citations

94433

37
h-index

123424

61
g-index

160
all docs

160
docs citations

160
times ranked

4405
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. <i>Addiction</i> , 2022, 117, 382-391.	3.3	22
2	Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. <i>Drug and Alcohol Review</i> , 2022, 41, 1009-1019.	2.1	25
3	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
4	Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the PELICAN™ study. <i>Epilepsy and Behavior</i> , 2022, 127, 108496.	1.7	7
5	Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with take-home naloxone™ in emergency departments. <i>EMA - Emergency Medicine Australasia</i> , 2022, 34, 509-518.	1.1	5
6	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. <i>Drug and Alcohol Review</i> , 2022, 41, 1095-1108.	2.1	11
7	What do general practitioners want from specialist alcohol and other drug services? A qualitative study of New South Wales metropolitan general practitioners. <i>Drug and Alcohol Review</i> , 2022, 41, 1152-1160.	2.1	4
8	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109388.	3.2	1
9	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. <i>Addiction Biology</i> , 2022, 27, e13125.	2.6	18
10	The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions. <i>Drug and Alcohol Review</i> , 2022, 41, 1085-1094.	2.1	1
11	Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. <i>Neuropsychopharmacology</i> , 2022, 47, 1315-1330.	5.4	28
12	Response to Steele and Acheson. <i>Drug and Alcohol Review</i> , 2022, , .	2.1	0
13	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708.	3.3	2
14	Assessing the concurrent validity, inter-rater reliability and test-retest reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. <i>Addiction</i> , 2021, 116, 1245-1255.	3.3	9
15	The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. <i>Journal of Sleep Research</i> , 2021, 30, e13211.	3.2	3
16	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	5.9	4
17	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. <i>JAMA Network Open</i> , 2021, 4, e219041.	5.9	55
18	Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. <i>BMJ Open</i> , 2021, 11, e044696.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108221.	2.8	13
20	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. <i>Drug and Alcohol Review</i> , 2021, , .	2.1	4
21	Opioid prescribing in Australia: too much and not enough. <i>Medical Journal of Australia</i> , 2021, 215, 117-118.	1.7	3
22	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients'™ experiences in Australia. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108959.	3.2	33
23	Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. <i>Drug and Alcohol Review</i> , 2021, 40, 567-571.	2.1	19
24	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	2.4	9
25	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
26	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	1.9	8
27	Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study. <i>Pain Medicine</i> , 2020, 21, 1188-1198.	1.9	3
28	Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence"Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 163.	5.1	0
29	Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. <i>Drug and Alcohol Review</i> , 2020, 39, 55-65.	2.1	12
30	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. <i>Accident Analysis and Prevention</i> , 2020, 148, 105784.	5.7	24
31	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	7.1	16
32	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108220.	3.2	19
33	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
34	Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. <i>Harm Reduction Journal</i> , 2020, 17, 26.	3.2	187
35	Providing take home naloxone needs to be improved to prevent opioid overdose deaths. <i>Medical Journal of Australia</i> , 2020, 212, 307-308.	1.7	2
36	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. <i>Drug and Alcohol Review</i> , 2020, 39, 441-446.	2.1	15

#	ARTICLE	IF	CITATIONS
37	Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. <i>CNS Drugs</i> , 2020, 34, 337-365.	5.9	105
38	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. <i>Drug and Alcohol Review</i> , 2020, 39, 356-364.	2.1	7
39	Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). <i>Harm Reduction Journal</i> , 2020, 17, 37.	3.2	72
40	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	1.9	9
41	Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. <i>Internal Medicine Journal</i> , 2019, 49, 1054-1055.	0.8	10
42	Nabiximols for the Treatment of Cannabis Dependence. <i>JAMA Internal Medicine</i> , 2019, 179, 1242.	5.1	68
43	Detection of ≥ 9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. <i>Drug Testing and Analysis</i> , 2019, 11, 1486-1497.	2.6	32
44	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. <i>Addiction</i> , 2019, 114, 1416-1426.	3.3	75
45	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724.	3.1	130
46	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	1.9	12
47	Regulatory and other responses to the pharmaceutical opioid problem. <i>Medical Journal of Australia</i> , 2019, 210, 6.	1.7	36
48	Survey of Australian psychiatrists' and psychiatry trainees' knowledge about and attitudes towards medicinal cannabinoids. <i>Australasian Psychiatry</i> , 2019, 27, 80-85.	0.7	21
49	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. <i>Journal of Addiction Medicine</i> , 2018, 12, 234-240.	2.6	18
50	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	7.4	28
51	Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs. <i>Drug and Alcohol Review</i> , 2018, 37, 472-479.	2.1	27
52	Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program. <i>Drug and Alcohol Review</i> , 2018, 37, 464-471.	2.1	34
53	Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination-Revised, and Montreal Cognitive Assessment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 107-122.	1.3	38
54	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018, 19, 533-540.	1.9	32

#	ARTICLE	IF	CITATIONS
55	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	2.1	5
56	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018, 8, e020745.	1.9	16
57	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e341-e350.	10.0	172
58	An overview of take-home naloxone programs in Australia. <i>Drug and Alcohol Review</i> , 2018, 37, 440-449.	2.1	37
59	Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. <i>BMC Psychiatry</i> , 2018, 18, 140.	2.6	17
60	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018, 8, e020723.	1.9	11
61	Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMSâ€16). <i>Medical Journal of Australia</i> , 2018, 209, 211-216.	1.7	66
62	Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. <i>Drugs</i> , 2018, 78, 1339-1352.	10.9	22
63	Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2018, 36, 67-78.	3.3	21
64	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017, 36, 311-316.	2.1	3
65	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	1.9	39
66	Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. <i>Drug and Alcohol Dependence</i> , 2017, 174, 181-191.	3.2	29
67	An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. <i>Epilepsy and Behavior</i> , 2017, 70, 334-340.	1.7	55
68	Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 967.	7.4	55
69	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017, 42, 1752-1765.	5.4	190
70	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2017, 181, 132-139.	3.2	27
71	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. <i>Mental Health and Physical Activity</i> , 2017, 13, 57-67.	1.8	5
72	Urinary cannabinoid levels during nabiximols (Sativexâ€)-medicated inpatient cannabis withdrawal. <i>Forensic Toxicology</i> , 2017, 35, 33-44.	2.4	19

#	ARTICLE	IF	CITATIONS
73	The Australian Treatment Outcomes Profile instrument as a clinical tool for older alcohol and other drug clients: A validation study. <i>Drug and Alcohol Review</i> , 2016, 35, 673-677.	2.1	15
74	Sleep Quality Among People Living With Chronic Noncancer Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 380-387.	1.9	10
75	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016, 157, 1489-1498.	4.2	43
76	Substance use, health status and service utilisation of older clients attending specialist drug and alcohol services. <i>Drug and Alcohol Review</i> , 2016, 35, 223-231.	2.1	14
77	Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. <i>BMC Psychiatry</i> , 2016, 16, 428.	2.6	8
78	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52.	3.2	27
79	Recommendations for the Prevention, Detection, Treatment and Management of Prescription Opioid Analgesic Dependence: Outcomes From the Opioid Analgesic Dependence Education Nexus (OPEN) Meeting. <i>International Journal of Mental Health and Addiction</i> , 2016, 14, 313-321.	7.4	12
80	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
81	Alprazolam use and related harm among opioid substitution treatment clients â€œ 12 months follow up after regulatory rescheduling. <i>International Journal of Drug Policy</i> , 2016, 36, 104-111.	3.3	18
82	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016, 162, 79-87.	3.2	40
83	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 70-75.	2.1	7
84	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
85	Injecting buprenorphineâ€naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629.	2.1	6
86	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333.	1.9	4
87	The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1153-1162.	2.6	16
88	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758.	1.9	78
89	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. <i>Pain Medicine</i> , 2015, 16, 356-366.	1.9	102
90	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. <i>European Respiratory Journal</i> , 2015, 46, 1202-1205.	6.7	11

#	ARTICLE	IF	CITATIONS
91	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> , 2015, 2, 314-322.	7.4	55
92	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015, 147, 144-150.	3.2	97
93	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
94	The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242.	4.2	104
95	Screening for alcohol and substance use for older people in geriatric hospital and community health settings. <i>International Psychogeriatrics</i> , 2015, 27, 157-166.	1.0	22
96	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	3.3	19
97	Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). <i>Addiction</i> , 2015, 110, 479-490.	3.3	23
98	Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. <i>Drug and Alcohol Review</i> , 2015, 34, 304-311.	2.1	25
99	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61.	2.8	20
100	Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal. <i>JAMA Psychiatry</i> , 2014, 71, 281.	11.0	209
101	Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014, 33, 27-32.	2.1	11
102	Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings. <i>Drug and Alcohol Review</i> , 2014, 33, 33-42.	2.1	77
103	Buprenorphine Diversion and Misuse in Outpatient Practice. <i>Journal of Addiction Medicine</i> , 2014, 8, 327-332.	2.6	6
104	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014, 136, 21-27.	3.2	43
105	Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. <i>Psychopharmacology</i> , 2014, 231, 4623-4636.	3.1	29
106	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 17.	2.4	39
107	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
108	Authors' reply. <i>British Journal of Psychiatry</i> , 2014, 204, 241-242.	2.8	1

#	ARTICLE	IF	CITATIONS
109	Exercise increases plasma THC concentrations in regular cannabis users. <i>Drug and Alcohol Dependence</i> , 2013, 133, 763-767.	3.2	34
110	Correlates of pain in an inpatient treatment sample of opioid-dependent people. <i>Drug and Alcohol Review</i> , 2013, 32, 489-494.	2.1	8
111	An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. <i>Pain Medicine</i> , 2013, 14, 62-74.	1.9	19
112	Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the randomised injectable Opiate Treatment trial, the UK's first supervised injectable maintenance clinics. <i>Drug and Alcohol Review</i> , 2013, 32, 566-573.	2.1	15
113	An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. <i>Drug and Alcohol Review</i> , 2013, 32, n/a-n/a.	2.1	10
114	Cost-effectiveness of injectable opioid treatment vs. oral methadone for chronic heroin addiction. <i>British Journal of Psychiatry</i> , 2013, 203, 341-349.	2.8	66
115	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. <i>Medical Journal of Australia</i> , 2013, 199, 696-699.	1.7	24
116	Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. <i>Medical Journal of Australia</i> , 2013, 198, 80-81.	1.7	32
117	Unplanned pregnancy and contraceptive use in women attending drug treatment services. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 146-150.	1.0	85
118	Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. <i>Australian Journal of Primary Health</i> , 2012, 18, 346.	0.9	15
119	The health impacts of khat: a qualitative study among Somali Australians. <i>Medical Journal of Australia</i> , 2011, 195, 666-669.	1.7	51
120	Investigating the effect on public behaviour of patients of a Medically Supervised Injectable Maintenance Clinic. <i>Drugs and Alcohol Today</i> , 2011, 11, 204-209.	0.7	1
121	Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. <i>Drug and Alcohol Review</i> , 2011, 30, 355-359.	2.1	14
122	Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation?. <i>Drug and Alcohol Review</i> , 2011, 30, 388-396.	2.1	57
123	Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia?. <i>Drug and Alcohol Review</i> , 2011, 30, 291-299.	2.1	28
124	Should I stay or should I go? Coming off methadone and buprenorphine treatment. <i>International Journal of Drug Policy</i> , 2011, 22, 77-81.	3.3	53
125	Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management. <i>American Journal on Addictions</i> , 2010, 19, 59-72.	1.4	92
126	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. <i>Addiction</i> , 2010, 105, 329-334.	3.3	20

#	ARTICLE	IF	CITATIONS
127	Commentary on Blanken <i>et al.</i> (2010): Long-term heroin-assisted treatment—some more questions and answers. <i>Addiction</i> , 2010, 105, 309-310.	3.3	1
128	Forming a national multicentre collaboration to conduct clinical trials: Increasing high-quality research in the drug and alcohol field. <i>Drug and Alcohol Review</i> , 2010, 29, 469-474.	2.1	6
129	The community impact of RIOTT, a medically supervised injectable maintenance clinic in south London. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2010, 3, 248-259.	0.5	4
130	Bioavailability of Buprenorphine from Crushed and Whole Buprenorphine (Subutex) Tablets. <i>European Addiction Research</i> , 2010, 16, 85-90.	2.4	17
131	Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. <i>Lancet, The</i> , 2010, 375, 1885-1895.	13.7	166
132	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. <i>Medical Journal of Australia</i> , 2009, 191, 161-165.	1.7	40
133	Why do patients report transferring between methadone and buprenorphine?. <i>Drug and Alcohol Review</i> , 2009, 28, 686-687.	2.1	10
134	Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. <i>Australian and New Zealand Journal of Public Health</i> , 2009, 33, 34-39.	1.8	3
135	Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. <i>Journal of Substance Abuse Treatment</i> , 2009, 37, 95-100.	2.8	45
136	Prescription of Heroin for the Management of Heroin Dependence. <i>CNS Drugs</i> , 2009, 23, 463-476.	5.9	48
137	[Commentary] FUTURE CHALLENGES FOR HEROIN AND OTHER OPIOID SUBSTITUTION TREATMENT. <i>Addiction</i> , 2008, 103, 967-968.	3.3	12
138	THE USE OF SUBLINGUAL BUPRENORPHINE-NALOXONE FOR REVERSING HEROIN OVERDOSE: A HIGH-RISK STRATEGY THAT SHOULD NOT BE RECOMMENDED. <i>Addiction</i> , 2008, 103, 2065-2066.	3.3	6
139	Unplanned admissions to two Sydney public hospitals after naltrexone implants. <i>Medical Journal of Australia</i> , 2008, 188, 441-444.	1.7	23
140	Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2007, 91, 187-194.	3.2	92
141	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 155-164.	0.5	15
142	Interactions on Mixing Diazepam With Methadone or Buprenorphine in Maintenance Patients. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 274-283.	1.4	63
143	Feasibility and Acceptability of an Intranasal Diamorphine Spray as an Alternative to Injectable Diamorphine for Maintenance Treatment. <i>European Addiction Research</i> , 2006, 12, 91-95.	2.4	16
144	Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD). <i>Australian and New Zealand Journal of Criminology</i> , 2006, 39, 171-189.	2.5	11

#	ARTICLE	IF	CITATIONS
145	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005, 30, 443-456.	3.0	23
146	Implementing Buprenorphine Treatment in Community Settings in Australia: Experiences from the Buprenorphine Implementation Trial. <i>American Journal on Addictions</i> , 2004, 13, S29-S41.	1.4	54
147	Methadone syrup injection in Australia: a sentinel finding?. <i>Addiction</i> , 2003, 98, 385-386.	3.3	5
148	A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. <i>Addiction</i> , 2003, 98, 1605-1613.	3.3	20
149	Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study. <i>Drug and Alcohol Dependence</i> , 2003, 70, 287-294.	3.2	24
150	Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. <i>Drug and Alcohol Dependence</i> , 2003, 71, 49-55.	3.2	48
151	A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. <i>Addiction</i> , 2002, 97, 1395-1404.	3.3	91
152	Buprenorphine dosing regime in the management of out-patient heroin withdrawal. <i>Drug and Alcohol Review</i> , 2002, 21, 39-45.	2.1	19
153	Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. <i>Medical Journal of Australia</i> , 2002, 176, 166-7.	1.7	21
154	Trends in licit opioid use in Australia, 1984-1998: comparative analysis of international and jurisdictional data. <i>Medical Journal of Australia</i> , 2000, 173, 524-527.	1.7	21
155	Methadone injecting in Australia: a tale of two cities. <i>Addiction</i> , 1999, 94, 1175-1178.	3.3	32
156	Cultural Adaptation and Psychometric Validation of the Australian Treatment Outcomes Profile for the Greek Population. <i>International Journal of Mental Health and Addiction</i> , 0, , 1.	7.4	1